Topical Corticosteroids on the Incidence of Postinflammatory Hyperpigmentation After QsNdYAG Laser

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-28

Study Completion Date

2016-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate the benefit of the application of topical high potency steroid on the incidence of post inflammatory hyperpigmentation after laser treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Pilot Study Testing 1064nm Q-switch Laser Versus Glycolic Acid Peels for the Treatment of Melasma

NCT01976273

Melanosis

COMPLETED NA

Effect of Cold Air Cooling on the Incidence of Post Inflammatory Hyperpigmentation Following Laser Treatment

NCT00287001

Nevus Hyperpigmentation

COMPLETED NA

Efficacy and Tolerability of Tested Formula After 3 Months of Treatment of Facial Hyperpigmentation of 3 Origins

NCT06253468

Hyperpigmentation

RECRUITING NA

Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial

NCT04597203

Melasma

UNKNOWN NA

Treatment of Melasma With Stabilized Kligman Preparation Associated or Not With Pulsed Dye Laser

NCT00863278

Melanosis

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* The incidence of post inflammatory hyperpigmentation (PIH) after treating lentigines with Q-switched Nd:YAG laser was 78.3%.
* It has been found that the incidence of PIH decreased to 40% after applied topical high potency steroid 2 days after the laser treatment.
* By these anti-inflammatory and anti-PIH effects of the high potency steroid, the investigators aimed that the application of steroid 2 days before and 2 days after the laser treatment would be better reduction in the incidence of PIH after Q-switched Nd:YAG laser.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lentigines Post Inflammatory Hyperpigmentation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

laser+steroid 2 days before and after laser

Before lentigines' treatment with Qs Nd:YAG 532 nm laser, topical 0.05% Clobetasol propionate ointment was applied 2 days on the lesion. Then applied 2 days after the treatment.

Group Type ACTIVE_COMPARATOR

topical 0.05% Clobetasol propionate ointment

Intervention Type DRUG

Apply only on the treated area twice a day as mentions

Q switched Nd:YAG laser 532 nm

Intervention Type DEVICE

Treatment of facial lentigines. The energy using depends on the endpoint of immediate whitening of the lesions.

laser+steroid 2 days after laser

Controlled side. Applied topical 0.05% Clobetasol propionate ointment only 2 days after the laser treatment

Group Type OTHER

topical 0.05% Clobetasol propionate ointment

Intervention Type DRUG

Apply only on the treated area twice a day as mentions

Q switched Nd:YAG laser 532 nm

Intervention Type DEVICE

Treatment of facial lentigines. The energy using depends on the endpoint of immediate whitening of the lesions.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

topical 0.05% Clobetasol propionate ointment

Apply only on the treated area twice a day as mentions

Intervention Type DRUG

Q switched Nd:YAG laser 532 nm

Treatment of facial lentigines. The energy using depends on the endpoint of immediate whitening of the lesions.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Having multiple lentigines on both sides of the face
* Fitzpatrick skin phototype 3-5

Exclusion Criteria

* Patients with lesions with any clinical suspicion of being pre-cancerous or skin malignancies of any kind
* Patients who have photosensitive dermatoses
* Pregnancy and lactation woman
* Patients with wound infections (herpes, other) on the day of treatment
* Patients with moderate and severe inflammatory acne, Immunosuppressed patients, history of vitiligo
* Patients with unrealistic concerns/expectations and inability to do the appropriate post-operative care

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes